Related Experiment Videos
Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of
E M Conner1, S Brand, J M Davis
1Department of Molecular and Cellular Physiology, Louisiana State University Medical Center, Shreveport 71130, USA.
Abstract:
The objectives of this study were to (1) assess the role of the 26S proteasome complex in regulating the expression of the inducible isoform of nitric oxide synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) in a model of chronic granulomatous colitis in vivo and (2) determine the role of the proteasome in regulating the inflammatory response observed in this model of chronic gut inflammation. The selective proteasome inhibitor MG-341 (0.3 mg/kg) was administered by gavage beginning immediately before the induction of colitis and continuing daily thereafter for the entire 14-day experimental period. We found that chronic proteasome inhibition using MG-341 significantly attenuated the peptidoglycan/polysaccharide (PG/PS)-induced up-regulation of iNOS in the colon and spleen and the consequent increase in plasma levels of nitrate and nitrite. Furthermore, we found that the proteasome inhibitor suppressed the up-regulation of the adhesion molecule VCAM-1 in the colon. We also found that MG-341 attenuated PG/PS-induced increases in macroscopic colonic inflammation, bowel wall thickness, colonic dry weight and colonic MPO activity. Treatment with MG-341 also significantly reduced PG/PS-induced increases in macroscopic spleen inflammation, spleen weight and spleen MPO activity. We conclude that the 26S proteasome complex plays an important role in regulating the PG/PS-induced up-regulation of iNOS and VCAM-1 in vivo and appears to be important in regulating colonic and splenic inflammation.
Insights
The 26S proteasome inhibitor MG-341 reduced inflammation in a chronic gut inflammation model. It attenuated inducible nitric oxide synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) upregulation, decreasing overall inflammation.
Area of Science:
- Biochemistry
- Immunology
- Gastroenterology
Background:
- Chronic gut inflammation involves complex molecular pathways.
- The 26S proteasome complex regulates protein degradation and cellular signaling.
- Inducible nitric oxide synthase (iNOS) and VCAM-1 are key inflammatory mediators.
Purpose of the Study:
- To investigate the 26S proteasome's role in regulating iNOS and VCAM-1 expression in chronic granulomatous colitis.
- To determine the proteasome's involvement in the inflammatory response within this disease model.
Main Methods:
- A rat model of chronic granulomatous colitis was induced using peptidoglycan/polysaccharide (PG/PS).
- The selective proteasome inhibitor MG-341 was administered daily for 14 days.
- Expression of iNOS, VCAM-1, and inflammatory markers (MPO activity, weight, thickness) were assessed in the colon and spleen.
Main Results:
- MG-341 significantly attenuated PG/PS-induced upregulation of iNOS in the colon and spleen.
- The proteasome inhibitor suppressed VCAM-1 upregulation in the colon.
- MG-341 reduced macroscopic colonic and splenic inflammation, associated tissue changes, and MPO activity.
Conclusions:
- The 26S proteasome complex plays a critical role in regulating iNOS and VCAM-1 expression in vivo.
- Proteasome inhibition effectively modulates inflammatory responses in experimental chronic gut inflammation.
- Targeting the 26S proteasome represents a potential therapeutic strategy for inflammatory bowel diseases.